<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455777</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 703802-CS4</org_study_id>
    <nct_id>NCT03455777</nct_id>
  </id_info>
  <brief_title>Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)</brief_title>
  <official_title>A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Patients With Homozygous Familial Hypercholesterolemia (HoFH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for
      reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous
      Familial Hypercholesterolemia (HoFH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of low density lipoprotein cholesterol (LDL-C).</measure>
    <time_frame>14 weeks</time_frame>
    <description>Percent change in LDL-C from Baseline to week 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of ISIS 703802 on plasma angiopoietin like 3 (ANGPTL3).</measure>
    <time_frame>7 and 14 Weeks</time_frame>
    <description>Absolute and percentage change in ANGPTL3 protein from Baseline to Week 14 will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ISIS 703802 on lipid parameters.</measure>
    <time_frame>7 and 14 Weeks</time_frame>
    <description>Absolute and percentage change from Baseline to Week 14 will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate plasma trough levels of ISIS 703802.</measure>
    <time_frame>14 Weeks</time_frame>
    <description>Plasma trough levels of ISIS 703802 during treatment period and those during post-treatment follow up period will be descriptively summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety of ISIS 703802 by the incidence of treatment-emergent adverse events</measure>
    <time_frame>14 Weeks</time_frame>
    <description>The safety of ISIS 703802 will be assessed by determining adverse effects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AKCEA-ANGPTL3-LRX Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKCEA-ANGPTL3-LRX</intervention_name>
    <description>Single open-label cohort</description>
    <arm_group_label>AKCEA-ANGPTL3-LRX Dose 1</arm_group_label>
    <other_name>ISIS 703802</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≤ 35 kg/m2,

          -  Genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene
             locus OR an untreated LDL-C &gt; 500 mg/dL (13 mmol/L) or treated LDL-C ≥ 300 mg/dL (2.59
             mmol/L) together with either cutaneous or tendon xanthoma before age 10 years OR
             familial medical history of genetically confirmed heterozygous FH in both parents OR
             untreated elevated LDL-C and TC &gt; 250 mg/dL consistent with the disease,

          -  Patients must be on stable LDL-C lowering agents or on regular apheresis

        Exclusion Criteria:

          -  Myocardial infarction, percutaneous transluminal coronary intervention, or coronary
             artery bypass graft surgery within 12 weeks prior to Screening, or cerebrovascular
             accident within 24 weeks prior to Screening.

          -  Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <phone>617-207-0289</phone>
    <email>clinicalstudies@akceatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akcea Therapeutics</last_name>
      <phone>6172070289</phone>
      <email>clinicalstudies@akceatx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

